RxDoctor Payments Data

Holly Brown, MD

Allergy & Immunology · Cedar Rapids, IANPI 1851382980

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.8% of the total across 222 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by GSK at 24.6% of the total.

$3,770in general payments, 2019–2025

Across 222 payments — averaging $16.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$926
  • AstraZeneca$631
  • Sanofi$473
  • Regeneron Healthcare Solutions, Inc.$434
  • Novartis$237
  • Phathom Pharmaceuticals, Inc.$121
  • plus $948 from 17 others

What the payments were for

  • Food & beverage$3,57395%
  • Education$1975%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,770 in reported general payments places this provider in the 80th percentile of 32 allergy & immunology providers in Iowa.

See all allergy & immunology providers in Iowa

Medicare billing

Part B allowed, 2024
$165,965
Medicare patients
189
Services billed
8,252

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$27,633
Arnuity ElliptaFluticasone Furoate50$15,367
Qvar RedihalerBeclomethasone Dipropionate24$8,660
Pulmicort FlexhalerBudesonide13$7,916
SymbicortBudesonide/Formoterol Fumarate14$7,141
Fluticasone-SalmeterolFluticasone Propion/Salmeterol41$4,612
Advair DiskusFluticasone Propion/Salmeterol18$4,271
Epinephrine28$4,135
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate22$2,709
Ipratropium Bromide73$2,533
Albuterol Sulfate HfaAlbuterol Sulfate77$2,155
Azelastine Hcl83$2,088
Montelukast Sodium257$1,981
Ventolin HfaAlbuterol Sulfate22$1,218
Fluticasone Propionate54$926

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Arnuity Ellipta$926$43,00082 claims
AstraZenecaPulmicort Flexhaler, Symbicort$631$15,05727 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 32 allergy & immunology providers in Iowa.

Other allergy & immunology in Cedar Rapids

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →